Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non-Current Liabilities (2017 - 2025)

Northwest Biotherapeutics (NWBO) has 14 years of Other Non-Current Liabilities data on record, last reported at $60.8 million in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 87.02% year-over-year to $60.8 million; the TTM value through Sep 2025 reached $60.8 million, up 87.02%, while the annual FY2024 figure was $46.2 million, 97.4% up from the prior year.
  • Other Non-Current Liabilities reached $60.8 million in Q3 2025 per NWBO's latest filing, up from $48.3 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $350.4 million in Q1 2021 and bottomed at $10.0 million in Q2 2023.
  • Average Other Non-Current Liabilities over 5 years is $95.0 million, with a median of $48.3 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: surged 1764.24% in 2021, then crashed 90.29% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $116.0 million in 2021, then fell by 21.8% to $90.7 million in 2022, then tumbled by 74.22% to $23.4 million in 2023, then soared by 97.4% to $46.2 million in 2024, then skyrocketed by 31.73% to $60.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $60.8 million in Q3 2025, $48.3 million in Q2 2025, and $47.2 million in Q1 2025.